Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$5.03 +0.37%

+$0.03 today

Market cap
$196.93M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.82M

Average 0.36M

TRDA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Entrada Therapeutics, Inc.NASDAQ: TRDA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of $70K fell 99.7% year over year, ahead of the -119.9% change in trailing-twelve-month gross profit. Sequentially, it fell 83.1% from the prior quarter.

Context

  • Gross profit amounted to 83.9% of revenue in FY2025, down 16.1 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -99.7% holds above the trailing-twelve-month pace of -119.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$70K-83.1% QoQ
Last fiscal yearDec 2025
$21.33M-89.9% YoY
LTMMar 2026
-$34.31M-119.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.7%——
1 year-89.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
21.33M USD
Year-over-year change
-89.9%

Gross Profit vs competitors

How TRDA compares with its peers on the latest reported figures

  • TRDA's LTM Mar 2026 gross profit of -$34.31M is the 8th highest of the 11 companies compared; the peer median is -$7.94M.
  • Its year-over-year change of -119.9% is the 7th highest of 9, against a peer median of -37.2%.
  • Gross profit amounts to 598.0% of revenue for TRDA, versus a peer median of 91.8%.
TRDA Competitors Peer median
Gross Profit for TRDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$201.36M +7.0%-4.1%92.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$41.35M -69.4%-32.2%91.2%
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 ———
ACHVAchieve Life Sciences, Inc.LTM Mar 2026-$111K ———
IMRXImmuneering CorporationLTM Mar 2026-$793.21K -354.2%——
HUMAHumacyte, Inc.LTM Mar 2026-$15.09M -917.5%—748.5%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$31.63M +46.9%—86.7%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-$34.31M -119.9%—598.0%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$40.76M -72.9%——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026-$42.41M -4.9%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$77.25M +23.8%——
Peer median (excluding TRDA) -$7.94M-37.2%-18.1%91.8%

Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00129.01M210.78M25.42M
Cost of Revenue00004.1M
Gross Profit00129.01M210.78M21.33M
Gross Margin——100.0%100.0%83.9%
Research & Development35.93M66.61M99.88M125.31M142.27M
Selling, General & Admin15.2M30.64M32.29M38.47M41.05M
Operating Expenses51.13M97.25M132.18M163.77M177.32M
Depreciation & Amortization1.12M1.9M2.84M3.77M425K
EBITDA(50.04M)(90.09M)14.9M70.26M(142.4M)
EBITDA Margin——11.5%33.3%-560.2%
Operating Income(51.13M)(97.25M)(3.16M)47.01M(156M)
Operating Margin——-2.5%22.3%-613.7%
Interest Income02.63M15.22M19.47M0
Interest Expense02.63M000
Other Income / Expenses(31K)2.63M15.22M19.47M13.17M
Income Before Tax(51.16M)(94.62M)12.06M66.49M(142.83M)
Pre-Tax Margin——9.3%31.5%-561.8%
Income Tax Expense0018.74M859K924K
Net Income(51.16M)(94.62M)(6.69M)65.63M(143.75M)
Net Margin——-5.2%31.1%-565.5%
EPS (Basic)(1.60)(2.79)(0.20)1.76(3.47)
EPS (Diluted)(1.60)(2.79)(0.20)1.68(3.47)
Weighted Avg Shares31.22M31.29M33.05M37.31M41.37M
Weighted Avg Shares (Diluted)31.22M31.29M33.05M39M41.37M

Entrada Therapeutics, Inc.

NASDAQ:TRDA

Intrinsic Alpha fair value

Locked

Current Price

$5.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.